WAVE LIFE SCIENCES LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
WAVE LIFE SCIENCES LTD. (WVE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.24 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 131.20K shares, a 73.81% decline year-over-year.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 5.10M shares, a 48.31% increase year-over-year.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 127.95K shares, a 10.34% decline year-over-year.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 960.50K shares, a 138.40% increase year-over-year.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.03M shares, a 32.75% decline from fiscal 2024.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 7.48M shares, a 29.67% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.77M shares, a 50.07% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.84M shares, a 4.63% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 131.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 5.24M shares 10-Q · filed 2026-07-30 | 5.36M shares derived: sum of 3 quarters · filed 2026-07-30 | 6.32M shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 5.10M shares 10-Q · filed 2026-04-28 | 5.23M shares derived: sum of 2 quarters · filed 2026-04-28 | 6.19M shares derived: sum of 3 quarters · filed 2026-04-28 | 6.69M shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 127.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.09M shares derived: sum of 2 quarters · filed 2026-02-26 | 1.59M shares derived: sum of 3 quarters · filed 2026-02-26 | 5.03M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 960.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.46M shares derived: sum of 2 quarters · filed 2025-11-10 | 4.90M shares 10-Q · filed 2025-11-10 | 5.05M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 500.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | 3.94M shares 10-Q · filed 2025-07-30 | 4.09M shares derived: sum of 3 quarters · filed 2025-07-30 | 4.49M shares derived: sum of 4 quarters · filed 2025-07-30 |
| 2025-03-31 | 3.44M shares 10-Q · filed 2025-05-08 | 3.58M shares derived: sum of 2 quarters · filed 2025-05-08 | 3.99M shares derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | 142.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 545.60K shares derived: sum of 2 quarters · filed 2025-03-04 | 7.48M shares 10-K · filed 2025-03-04 | |
| 2024-09-30 | 402.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 7.34M shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 6.93M shares 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | 5.77M shares 10-K · filed 2024-03-06 | |||
| 2022-12-31 | 3.84M shares 10-K · filed 2023-03-23 | |||
| 2021-12-31 | 3.67M shares 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |